"Antonio Perrino" Division of Medical Oncology Strada Statale 7 APPIA
Welcome,         Profile    Billing    Logout  
 14 Trials 
14 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cinieri, Saverio
TOP, NCT00637325: Trastuzumab Optimization Trial in Breast Cancer

Recruiting
3
500
Europe
trastuzumab, Herceptin
Regione Lombardia, Mario Negri Institute for Pharmacological Research, Istituto Clinico Humanitas
Metastatic or Locally Advanced Breast Cancer
05/09
04/11
OVER, NCT02394496: Overcoming Endocrine Resistance in Metastatic Breast Cancer

Recruiting
3
396
Europe
Fulvestrant, Faslodex, Lapatinib, Aromatase Inhibitors, Aromatase Inhibitor, Placebo Lapatinib, Placebo
Consorzio Oncotech
Metastatic Breast Cancer
12/16
01/17
INNOVATE-3, NCT03940196: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / )

Checkmark [VIRTUAL] Evaluation of the Safety of Tumor Treating Fields (TTFields) Application to the Torso – in Vivo Studies
Checkmark [VIRTUAL] Evaluating the safety of Tumor Treating Fields (TTFields) application to the torso – in vivo studies
Checkmark [VIRTUAL] Evaluating the safety of Tumor Treating Fields (TTFields) application to the torso – in vivo studies
Checkmark Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase III INNOVATE-3/ENGOT-ov50 study
Checkmark [VIRTUAL] Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum- resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3
More
Recruiting
3
540
Europe, Canada, US, RoW
NovoTTF-100L(O), TTFields, Paclitaxel, Weekly Paclitaxel, Taxol
NovoCure Ltd.
Ovarian Cancer
09/23
09/23
eMonarcHER, NCT04752332 / 2020-004035-24: A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Checkmark [VIRTUAL] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Recruiting
3
2450
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Standard Adjuvant ET, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms
05/25
02/33
APTneo, NCT03595592 / 2017-000981-31: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Recruiting
3
650
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Carboplatin, Carboplatin Hospiria, Paclitaxel, Paclitaxel Hospiria, Doxorubicin, Doxorubicin Pfizer, Cyclophosphamide, Cyclophosphamide Sandoz, Atezolizumab, Tecentriq, Surgery
Fondazione Michelangelo, Hoffmann-La Roche
Invasive Breast Cancer
12/26
06/27
GIM10-CONSENT, NCT02918084 / 2013-001629-23: CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

Checkmark [VIRTUAL] Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor.…
Checkmark [VIRTUAL] Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor.…
Recruiting
3
1000
Europe
Anastrozole or Letrozole or Exemestane, Clinical Practice, Experimental arm
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Cancer
06/28
06/28
NCT02238509 / 2013-005044-29: Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Recruiting
2
154
Europe
Lapatinib, Tyverb, Trastuzumab, Herceptin
Consorzio Oncotech, Clinical Research Technology
Metastatic Breast Cancer
10/17
10/17
Nabster, NCT03219762 / 2016-000408-27: Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC

Checkmark Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Checkmark Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER TRIAL)
Recruiting
2
65
Europe
Nabpaclitaxel, Abraxane
Gruppo Oncologico Italiano di Ricerca Clinica, Temas srl, Clirest s.r.l., Mipharm S.p.A., Istituto Toscano Tumori - Centro per il Coordinamento delle Sperimentazioni Cliniche
Small Cell Lung Cancer
01/19
01/19
BEAT, NCT03896074 / 2018-003973-82: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients

Not yet recruiting
2
206
Europe
Atezolizumab, Bevacizumab
Fondazione Ricerca Traslazionale, Roche S.p.A.
Non-small-cell Lung Cancer Patients
05/22
04/23
CeLEBrATE, NCT04730999 / 2019-003798-25: Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

Recruiting
2
52
Europe
Etoposide, Carboplatin, Bevacizumab, Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma, Italy, YGHEA, CRO Division of Ecol Studio spa, Dr. Luca Boni U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino - IST NORD CBA
Small Cell Lung Cancer
06/23
10/24
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting
2
168
Europe
Palbociclib
Consorzio Oncotech, Pfizer
Metastatic Breast Cancer, Locally Advanced Breast Cancer
07/23
07/23
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/20
07/21
NCT02895165: PREgnancy and FERtility Registry

Checkmark The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer.
Checkmark The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients.
Checkmark The pregnancy and fertility (PREFER) study: A prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Neoplasms, Pregnancy, Fertility Preservation
11/27
11/32
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Recruiting
N/A
150
Europe
Regorafenib 40 MG Oral Tablet [STIVARGA]
Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme
08/22
08/22

Download Options